Skip to main content
Moderna10-Q: AI investment

Moderna prioritizes AI investments to support late-stage clinical development.

What happened

Amid significant cash outflows and a $1.3B net loss, Moderna is explicitly calling out investments in artificial intelligence technologies as a strategic priority. This signals a strong need for AI-powered solutions to enhance R&D productivity, optimize clinical trials, and accelerate time-to-market for its pipeline candidates.

Source

SEC EDGARMay 1, 2026

Quarterly report (Form 10-Q)

Moderna 10-Q

Filing excerpt

We anticipate maintaining substantial expenses across all areas of our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. This also extends to our manufacturing costs, including our arrangements with our supply and manufacturing partners. Our ongoing work on our... late-stage clinical development, investments in digital capabilities and artificial intelligence technologies... will require significant cash outflows in future periods...

sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-Q: AI investment

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
03/31
Filed
May 1, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
1682852
Accession number
0001682852-26-000060
Metric named
Significant cash outflows required for investments in AI.
Timeframe
Current year
Filing year
2026
Fiscal year
0
Why it matters
Target for AI vendors
Signal category
Technology

Topics and mentions

Technologies

  • artificial intelligence

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
May 5, 2026
signal_type
sec-10q
signal_subtype
aiInvestment

Use this data

Get every 10-Q signal for Moderna and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/9eedfcae-f985-44f9-8e3a-467bb884f54d returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.

{
  "signal_id": "9eedfcae-f985-44f9-8e3a-467bb884f54d",
  "signal_type": "sec-10q",
  "signal_subtype": "aiInvestment",
  "detected_at": "2026-05-05T08:48:21.328+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "detail": "Amid significant cash outflows and a $1.3B net loss, Moderna is explicitly calling out investments in artificial intelligence technologies as a strategic priority. This signals a strong need for AI-powered solutions to enhance R&D productivity, optimize clinical trials, and accelerate time-to-market for its pipeline candidates.",
    "metrics": {
      "timeframe": "current_year",
      "dollar_context": "Significant cash outflows required for investments in AI."
    },
    "summary": "Moderna prioritizes AI investments to support late-stage clinical development.",
    "excerpts": "We anticipate maintaining substantial expenses across all areas of our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. This also extends to our manufacturing costs, including our arrangements with our supply and manufacturing partners. Our ongoing work on our... late-stage clinical development, investments in digital capabilities and artificial intelligence technologies... will require significant cash outflows in future periods...",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htm",
    "filing_date": "2026-05-01",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "03/31",
    "sales_relevance": "Target for AI vendors",
    "signal_category": "technology",
    "technologies_mentioned": [
      "artificial intelligence"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.